身体活动和久坐时间与有或没有虚弱的老年人功能障碍之间的剂量反应关系:一个前性队列研究
Satoshi Seino1, Takumi Abe1, Yu Nofuji1
1Research Team for Social Participation and Healthy Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Frontiers in public health
|May 9, 2024
概括
较高的体力活动 (PA) 降低了老年人功能障碍 (FD) 的风险. 增加PA对于脆弱个体至关重要,而减少久坐时间 (ST) 对于非脆弱的老年人来说是预防FD的关键.
科学领域:
- 老年学是一门学科.
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 功能障碍 (FD) 在老年人群中越来越令人担忧.
- 了解身体活动 (PA),久坐时间 (ST) 和FD之间的关系对于开发有针对性的干预措施至关重要.
- 脆弱状态对这些关联的影响仍然未被充分探索.
研究的目的:
- 调查中度至强度体力活动 (MVPA) 和ST与FD发病率之间的剂量反应关系.
- 为了检查这些关联是否在脆弱和非脆弱的老年人之间有所不同.
主要方法:
- 在日本对7480名老年人 (65-84岁) 进行前性队列研究.
- 使用国际体育活动问卷-简单表格进行评估的MVPA和ST.
- 通过国家长期护理保险数据库识别的FD;使用检查清单15评估脆弱性.
主要成果:
- 较高的MVPA水平显示出剂量反应关系,显著降低了FD风险,在3000-4000METs·min/week时观察到最佳益处.
- 增加的ST (≥600分钟/天) 与更高的FD风险有关,特别是在非脆弱个体中.
- 在脆弱和非脆弱群体中,MVPA的保护作用是一致的,尽管脆弱个体中协会的大小更强.
结论:
- 较高的MVPA始终降低了老年人中的FD发病率,无论其脆弱状态如何.
- 减少长期的ST对于预防FD很重要,特别是在非脆弱的个体中.
- 对于脆弱的老年人来说,为了预防FD,强烈建议增加MVPA,即使是小幅增加.
相关概念视频
01:15Drug Dosing: Geriatric Patients
402
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
402
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
387
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
387
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
406
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
406
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
358
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
358
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
378
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
378